*Access Campaign, Médecins Sans Frontières, Geneva, Switzerland; and
†Centre for Infectious Disease Epidemiology and Research, University of Cape Town, South Africa.
Correspondence to: Kimberly Bonner, MPA, MSF Access Campaign, Médecins Sans Frontières, Rue de Lausanne 78, P.O Box 116, CH-1211 Geneva 21, Switzerland (e-mail: Kimberly.email@example.com).
K.B. and A.M. contributed equally to this manuscript.
The authors have no funding or conflicts of interest to disclose.
N.F. conceived and designed the review, conducted the meta-analysis, and provided critical feedback; A.M. acquired articles, conducted full text searches, data abstraction, and drafted the article; K.B. conducted title and abstract search and full text searches, data abstraction, and drafted the article; T.R. provided critical edits; and J.C. provided substantial design support and edits to the manuscript.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s Web site (www.jaids.com).
Received February 28, 2013
Accepted June 01, 2013
There is an increasing appreciation for the benefits of routine viral load monitoring as a tool to provide an early indication of risk for treatment failure and reinforce adherence.1,2 For patients in whom a detectable viral load is the result of poor adherence, timely identification of viremia provides an opportunity to reinforce adherence before the development of resistance mutations and, thus, maintain the efficacy of the patient’s current antiretroviral therapy (ART) regimen.3 Subsequent follow-up viral load tests will document whether the patient is able to achieve viral suppression again4 or if the patient remains viremic, potentially triggering a genotype test to document resistance or an empiric regimen change.2
The World Health Organization (WHO)5 recognizes the importance of regular monitoring, including viral load, for reinforcing adherence to ART,6 and the 2010 WHO Guidelines for ART in resource-limited settings propose an algorithm for using viral load as a means for discriminating between patients in need of adherence support and those who require a switch to second-line therapy.5 Recognizing the benefit of this approach, the 2010 WHO guidelines also recommend that countries begin to phase in virological monitoring. However, capacity to implement routine viral load testing remains limited in many resource-constrained settings, leading to debate about the relative importance of viral load within a public health approach.7,8
This systematic review assesses the impact of routine viral load monitoring on achieving virological resuppression in viremic patients.
Using a sensitive search strategy as part of a predefined protocol (see Appendix S1, Supplemental Digital Content, http://links.lww.com/QAI/A437), we searched PubMed, EMBASE, CABS Abstracts, Cochrane Central Register of Controlled Trials, LILACS, and AMED databases up to November 2012 for studies that reported on the targeted use of an adherence intervention following an initial viral load and reported virological outcomes following the intervention. No language, date, or geographical exclusions were applied. We further searched the abstract databases of the International AIDS Society, Conferences on Retroviruses and Opportunistic Infections, and the MSF Scientific Day, from 2011 to May 2013, to identify recent studies that have not yet been published in full. After an initial title screen, full text copies of potentially eligible articles were reviewed independently by 2 reviewers. A title search of references was performed on articles meeting the inclusion criteria to determine potential articles for inclusion, which were not identified using the initial database search. After all articles meeting the inclusion criteria were identified, data were abstracted by 2 independent reviewers according to the prespecified categories. Confirmations were requested from investigators when needed.
Articles were excluded if they had fewer than 2 viral load test rounds, if follow-up testing differed greatly between intervention and control groups (for comparative studies), if patients were antiretroviral naive or had been started on ART within the preceding 6 months, or if none of the outcomes of interest were reported. Viremia was defined based on thresholds defined by the studies. Articles were omitted from the review if they were judged to be at high risk of bias for the outcome of interest (ie, if other factors, such as changes in medication during the study, may have influenced resuppression rates). No restrictions were placed on the study design.
For studies reporting the proportion of patients resuppressing following an adherence intervention, data were pooled using random-effects meta-analysis following stabilization of the variance of raw proportions using a Freeman–Tukey type arcsine square-root transformation. Studies that did not have the same outcome measure (proportion resuppressed) were excluded from the meta-analysis, as these could not be directly compared statistically. All analyses were conducted using Stata version 12 (StataCorp, LP, College Station, TX).
Approximately 4279 titles were identified using the initial database search and taken for abstract review, of which 183 articles were read in full. Overall, 14 were identified, from which 6 met eligibility for the review; 2,047 conference abstracts were also screened and identified 2 additional studies for review (see Appendix S2, Supplemental Digital Content, http://links.lww.com/QAI/A437). Characteristics for the studies included are described in Table 1.
The selected studies were published between 2004 and 2013 and reported data from 8 countries: South Africa,9,10 the United States,11 Thailand,6 Mali and Burkina Faso,12 the Kingdom of Swaziland,13 India,8 and France.14 Five studies reported outcomes in terms of viremic resuppression in addition to viral load monitoring.6,9,10,13,15 Follow-up period for the included studies varied from at least 3 months13,15 to 6 months6,9,10 to 4 years.9 Of the 6 articles identified from the literature review for this study, 6 were retrospective cohorts6,8,9,11,13,14 and 2 prospective cohorts.10,12
The studies defined different thresholds for viremia: >50 copies per milliliter6,8,13; >200 copies per milliliter14; >400 copies per milliliter9; >500 copies per milliliter12; and >1000 copies per milliliter10; and 1 did not specify the viremic threshold.11 Similarly, viremic resuppression was defined differently: <50 copies per milliliter6,8,11,12; <100 copies per milliliter13; <200 copies per milliliter14; <400 copies per milliliter9; or <1000 copies per milliliter.10
Patient characteristics and reporting periods varied across studies. One study included children and adults,6 and the rest included adults alone8,10,11,13 or did not specify age.8,9,12,14 Although 1 prospective cohort collected data from the onset of treatment, the other 7 provided data starting with the detection of a raised viral load.6,8,9,11–14 All studies included patients who had already begun ART. Two studies noted that all patients had been enrolled in treatment for at least six months prior to the onset of viral load monitoring.6,12 One study provided additional unpublished data on resuppression in their cohort.9
There was substantial variability in the type and duration of adherence support interventions. These interventions included peer support, adherence counselors, peer counselors, educational sessions, home visits, adherence support tools, and short-term directly observed therapy.6,8–12,14
Study quality was assessed according to modified Newcastle Ottawa criteria (see Appendix S3, Supplemental Digital Content, http://links.lww.com/QAI/A437) and was judged overall to be moderate. Most studies (6) were retrospective cohorts, but all provided objective outcome measures with appropriate statistical analysis; 3 discussed sources of bias and most (5) assessed generalizability of the findings.
All studies documented reductions in numbers of viremic patients between the first detectable viral load and subsequent viral loads. These reductions were statistically significant, where such analysis was done. One study reported data as time to event and estimated that, by 32 months, only 5.6% patients will have failed virologically (2 consecutive viral load tests over 1000).10 Five studies reported on the proportion of patients resuppressing after an adherence intervention; this ranged from 54.2% [95% confidence interval (CI): 46.3% to 62.0%]13 to 89.1% (95% CI 77.8-96.7%),6 with a pooled proportion of 70.46% (95% CI: 56.6% to 84.4%, τ2 = 0.11) (Fig. 1). The lowest proportion of resuppression was reported by Pirkle et al12 in which only a third of participants achieved >1 log viral load reduction; however, this cohort had been on ART an average of 23.7 months before viral load monitoring was initiated, and there was a high rate of accumulated ART resistance mutations that had developed before the adherence intervention. The highest proportion of resuppression (90%) was reported by a study that focused on a subset of patients with viremia between 50 and 1000 copies per milliliter.6
This review found that, in all studies, the majority of patients in whom viremia is initially detected resuppress following an adherence intervention, and all studies showed a subsequent reduction in viral load levels.
Targeted adherence interventions triggered by viral load monitoring may allow patients to stay on more affordable, less complex, first-line regimens, with clear benefits for both the patient and healthcare system.3,16,17 On average, second-line HIV treatments are at least 3 times the price of first-line medications in low-income countries.18 Models predict that up to 80% of drug-resistant transmission could be reduced by yearly virological monitoring.19 Timing of intervention is crucial. In 1 study included in this review, where routine viral load testing began later in the treatment cycle, more than 60% patients had already developed resistance mutations when viral load testing started,12 suggesting that early viral load monitoring (ie, within 12 months of ART initiation) is critical for identifying early treatment failure. Of particular note is the 78% resuppression for patients suspected of failing second-line treatment; robust third-line options are not widely available in many low-income countries because of high cost, and viral load may be a particularly cost-effective intervention for these patients.
Although there is a clear rationale and recommendation for routine viral load testing, few low-resource countries have implemented this widely. A recent survey of 23 low- and middle-income countries found that only 4 incorporated routine viral load monitoring into their national guidelines, and only Brazil, Botswana, and South Africa actually have viral load testing readily available for this purpose.20
As viral load monitoring is expanded, operational research is needed to inform the optimal adherence intervention, the frequency of viral load testing, the most appropriate virologic thresholds to use, and the optimal use of point-of-care technologies.21 The development of simpler, automated devices (whether point-of-care or laboratory based, using dried blood spots) is anticipated to greatly enhance the ability of resource-limited countries to implement viral load testing, particularly at peripheral sites.7
The aim of this review was to systematically assess the reported proportion of patients who resuppress following an adherence intervention, not to determine the causal effect of viral load on adherence. Such estimates of resuppression should be taken as indicative only and, in programs, can be expected to vary according to the presence of drug resistance (which may be influenced by regimen efficacy, prior treatment exposure, time on treatment, and prevalence of transmitted drug resistance) and the effectiveness of the actual adherence intervention. Nevertheless, the findings of this review support the benefit of viral load testing as a tool to detect adherence problems and to allow substantial numbers of patients to achieve viral resuppression posttargeted adherence counseling. Additional studies can determine the optimal adherence–counseling package.
In conclusion, these observational studies show that routine viral load monitoring is beneficial when used as a tool to identify people in need of adherence interventions, the majority of whom resuppress and are able to continue their treatment after adherence support.
Special thanks to Alexandra Calmy, Eric Goemaere, and Lucy Ann Parker for clarifications and additional data on their studies.
1. Bartlett JA, Shao JF. Successes, challenges, and limitations of current antiretroviral therapy in low-income and middle-income countries. Lancet Infect Dis. 2009;9:637–649.
2. Keiser O, Chi BH, Gsponer T, et al.. Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa. AIDS. 2011;25:1761–1769.
3. Ajose O, Mookerjee S, Mills EJ, et al.. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. AIDS. 2012;26:929–938.
4. El-Khatib Z, Delong AK, Katzenstein D, et al.. Drug resistance patterns and virus re-suppression among HIV-1 subtype C infected patients receiving non-nucleoside reverse transcriptase inhibitors in South Africa. J AIDS Clin Res. 2011;2.
5. WHO. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach. Geneva, Switzerland: WHO Press; 2010. pp. 47–52, 61.
6. Wilson D, Keiluhu AK, Kogrum S, et al.. HIV-1 viral load monitoring: an opportunity to reinforce treatment adherence in a resource-limited setting in Thailand. Trans R Soc Trop Med Hyg. 2009;103:601–606.
7. Roberts T, Bygrave H, Fajardo E, et al.. Challenges and opportunities for the implementation of virological testing in resource-limited settings. J Int AIDS Soc. 2012;15:17324.
8. Khan S, Petros I, Andries A, et al.. Second-Line Failure and First Experiences With Third-Line Antiretroviral Therapy in Mumbai, India. London, UK: MSF Scientific Day Abstract; 2013.
9. Calmy A, Ford N, Hirschel B, et al.. HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis. 2007;44:128–134.
10. Orrell C, Harling G, Lawn SD, et al.. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther. 2007;12:83–88.
11. DeFino M, Clark J, Mogyoros D, et al.. Predictors of virologic success in patients completing a structured antiretroviral adherence program. J Assoc Nurses AIDS Care. 2004;15:60–67.
12. Pirkle CM, Boileau C, Nguyen VK, et al.. Impact of a modified directly administered antiretroviral treatment intervention on virological outcome in HIV-infected patients treated in Burkina Faso and Mali. HIV Med. 2009;10:152–156.
13. Parker LA, Kiran J, Azih C. Use of Viral Load (VL) Monitoring to Enable Better Targeting of Adherence Support for Antiretroviral Therapy (ART) Compliance in Swaziland. London, UK: MSF Scientific Day Abstract; 2013.
14. Berki-Benhaddad Z, Ecobichon JL, Mentre F, et al.. [Adherence intervention for HIV-infected patients receiving antiretroviral treatment. Implementation and initial assessment]. Presse Med. 2006;35(9 Pt 1):1241–1248.
15. Kahn JG, Marseille E, Moore D, et al.. CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectiveness study. BMJ. 2011;343:.
16. Hamers RL, Sawyer AW, Tuohy M, et al.. Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis. AIDS. 2012;26:1663–1672.
17. Kimmel AD, Weinstein MC, Anglaret X, et al.. Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. J Acquir Immune Defic Syndr. 2010;54:258–268.
18. Renaud-Thery F, Avila-Figueroa C, Stover J, et al.. Utilization patterns and projected demand of antiretroviral drugs in low- and middle-income countries. AIDS Res Treat. 2011;2011:749041.
19. Hoare A, Kerr SJ, Ruxrungtham K, et al.. Hidden drug resistant HIV to emerge in the era of universal treatment access in Southeast Asia. PloS One. 2010;5:.
20. MSF MSF. Speed Up Scale-Up: Strategies, Tools and Policies to Get the Best Treatment to More People, Sooner. Geneva, Switzerland: MSF Access Campaign; 2012.
21. MSF MSFAC. Undetectable: How Viral Load Monitoring Can Improve HIV Treatment in Developing Countries. Geneva, Switzerland: MSF Access Campaign; 2012.